Locus Biosciences – a precision medicine company spun out from N.C. State University– is moving toward human trials, according to CEO Paul Garofolo.
The company was formed back in May 2015 and is using a version of the genome editing technology known as the CRISPR-Cas system to develop therapeutics that are aimed at targeting antibiotic resistant bacterial infections without killing normally-occurring or “good” bacteria.
As of last summer, Locus Biosciences felt it “had what we needed…
Locus Biosciences – a precision medicine company spun out from N.C. State University– is moving toward human trials, according to CEO Paul Garofolo.
The company was formed back in May 2015 and is using a version of the genome editing technology known as the CRISPR-Cas system to develop therapeutics that are aimed at targeting antibiotic resistant bacterial infections without killing normally-occurring or “good” bacteria.
As of last summer, Locus Biosciences felt it “had what we needed…